Evidence map›Paper›PMID 25785460›Full record

Trial reportPloS one2015

A predictive model for corticosteroid response in individual patients with MS relapses.

Martin Rakusa, Stefan J Cano, Bernadette Porter, Afsane Riazi, Alan J Thompson, Jeremy Chataway, Todd A Hardy

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Martin RakusaQueen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute of Neurology, University College London and National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Stefan J CanoClinical Neurology Research Group, Room N16 ITTC Building, Plymouth University Peninsula Schools of Medicine and Dentistry, Tamar Science Park, Davy Road, Plymouth, United Kingdom.
Bernadette PorterQueen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute of Neurology, University College London and National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Afsane RiaziUniversity College London, Institute of Neurology, Dept of Brain Repair and Rehabilitation, London, United Kingdom; Department of Psychology, Royal Holloway, University of London, Surrey, United Kingdom.
Alan J ThompsonQueen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute of Neurology, University College London and National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, United Kingdom; University College London, Institute of Neurology, Dept of Brain Repair and Rehabilitation, London, United Kingdom.
Jeremy ChatawayQueen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute of Neurology, University College London and National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Todd A HardyQueen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute of Neurology, University College London and National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, United Kingdom; MS Clinic, Brain & Mind Research Institute, University of Sydney, Sydney, Australia; Neuroimmunology Clinic, Concord Repatriation General Hospital, Sydney, Australia.
University College London · GBUniversity College London Hospitals NHS Foundation Trust · GBNational Hospital for Neurology and Neurosurgery · GBRoyal Holloway University of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo derive a simple predictive model to guide the use of corticosteroids in patients with relapsing remitting MS suffering an acute relapse. MATERIALS AND

methodsWe analysed individual patient randomised controlled trial data (n=98) using a binary logistic regression model based on age, gender, baseline disability scores [physician-observed: expanded disability status scale (EDSS) and patient reported: multiple sclerosis impact scale 29 (MSIS-29)], and the time intervals between symptom onset or referral and treatment.

resultsBased on two a priori selected cut-off points (improvement in EDSS ≥ 0.5 and ≥ 1.0), we found that variables which predicted better response to corticosteroids after 6 weeks were younger age and lower MSIS-29 physical score at the time of relapse (model fit 71.2% - 73.1%).

conclusionsThis pilot study suggests two clinical variables which may predict the majority of the response to corticosteroid treatment in patients undergoing an MS relapse. The study is limited in being able to clearly distinguish factors associated with treatment response or spontaneous recovery and needs to be replicated in a larger prospective study.

Indexed as

Models, StatisticalAdrenal Cortex HormonesAdultFemaleHumansMaleMultiple Sclerosis, Relapsing-RemittingPrognosisTreatment OutcomeAdrenal Cortex Hormones

Identifiers

PMID25785460
PMCPMC4364957
OpenAlexW2073700351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.